Quality CareFind out why Mayo Clinic is the right place for your health care. Make an appointment.
Meet the StaffFind a directory of doctors and departments at all Mayo Clinic campuses. Visit now.
Research and Clinical TrialsSee how Mayo Clinic research and clinical trials advance the science of medicine and improve patient care. Explore now.
Visit Our SchoolsEducators at Mayo Clinic train tomorrow’s leaders to deliver compassionate, high-value, safe patient care. Choose a degree.
Professional ServicesExplore Mayo Clinic's many resources and see jobs available for medical professionals. Get updates.
Philanthropy at Mayo ClinicYour support accelerates powerful innovations in patient care, research and education. Give today.
Search Results 11-20 of 61 for Oral
Sign up Related Content Article Mayo researchers say oral apixaban safe and effective for treating blood clots in cancer patients
Very rapid taper of oral corticosteroids soon after initiating anti-IL-5 therapy is not advised due to risk of an asthma flare.
Sign up Related Content Article Tofacitinib is first oral medication approved for use in treating moderate to severe ulcerative colitis Article Head-to-head comparison between vedolizumab and adalimumab for treatment of moderately to...
Oral airway If ventilation is inadequate with the BVM, an adjunct oral airway device can help keep the airway open.
Some patients have almost no discomfort while others require significant amounts of oral narcotics and report pain of 10 out of 10 on a numerical rating scale.
It highlights current trends and advances in pulmonary and critical care medicine at Mayo Clinic. 2019 Issues Vol. 35, No. 1, 2019 (PDF) Ion Robotic Bronchoscopy System the Focus of a Multicenter Trial Management of Fibrosing Mediastinitis Updates in...
Clarke outlines: "Treatment with oral calcium and active vitamin D in divided doses each day is currently the standard of care, occasionally supplemented with magnesium, thiazide-type diuretics or phosphate binders, but this does not...
Daclatasvir plus sofosbuvir Daclatasvir plus sofosbuvir is an all-oral, once-daily regimen for difficult-to-treat genotype 3.
Related Content Article Comparing the risk of gastrointestinal bleeding associated with direct oral anticoagulants Receive Mayo Clinic news in your inbox.
Tofacitinib Approved in 2018, tofacitinib is a selective Janus kinase (JAK) inhibitor and the first oral medication approved for treatment of moderate to severe ulcerative colitis.
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic.
Mayo Clinic is a nonprofit organization and proceeds from Web advertising help support our mission. Mayo Clinic does not endorse any of the third party products and services advertised.
A single copy of these materials may be reprinted for noncommercial personal use only. "Mayo," "Mayo Clinic," "MayoClinic.org," "Mayo Clinic Healthy Living," and the triple-shield Mayo Clinic logo are trademarks of Mayo Foundation for Medical Education and Research.